Bioengineer.org | Delamanid Resistance Emerges Rarely During Multidrug-Resistant TB Treatment in China
7 November 2026
Bioengineer.org news story
A prospective multicenter cohort study tracking 263 patients with culture-confirmed multidrug-resistant or rifampicin-resistant TB across ten medical centers in China has revealed that primary resistance to delamanid is exceedingly rare, occurring in just 0.76 percent of tested isolates. Conducted between 2020 and 2024, the nationwide surveillance investigation evaluated the in vitro susceptibility dynamics of Mycobacterium tuberculosis isolates obtained from individuals receiving delamanid-containing regimens. Among the 263 patients who completed their therapeutic courses, favorable treatment outcomes were documented in 187 individuals, representing an overall success rate of 71.1 percent, while the remaining 76 participants, or 28.9 percent, experienced unfavorable clinical outcomes. The baseline susceptibility profile demonstrated that the vast majority of bacterial isolates remained innately susceptible to the drug. Furthermore, longitudinal monitoring revealed that the emergence of acquired drug resistance during the entire treatment period was extraordinarily infrequent, providing critical clinical evidence regarding the durability of delamanid within multidrug-resistant TB treatment combinations.
Read the full news story here.
Source: Bioengineer.org
